- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
-
Tuesday, November 24th
Still Believe in Antigenics
-
Is America Ready for Assembly Line Medicine?
-
BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO
-
CytRx Corporation: Key Developments Ahead
-
Abbott Acquires Global Rights to Chronic Pain Treatment
-
Value Investors Know Insmed's Cash Wealth Offers No Margin of Safety
-
Greenlight's Einhorn Exits Energy, Focuses on Healthcare
-
Monday, November 23rd
Genzyme's Very Bad Year
-
Earnings Preview: Medtronic
-
Bristol-Myers Receives Approval for Autism Drug
-
Healthcare Reform: Is It Worthwhile? Can We Afford It?
-
Techne Corporation: Good Risk/Reward Proposition
-
Sunday, November 22nd
Spectrum Pharma: Zevalin Sales Ramp Up
-
Forbes Best Small Companies for 2009: Part III
-
Diabetes Care: Global Investing Opportunities
-
Friday, November 20th
Vitamin Beats Statin: Is Merck's Zetia in Trouble?
-
King Pharma Marches Higher
-
What the Senate Health Bill Will Really Cost
-
BioMed News Bytes: AstraZeneca, Delcath, Unilife
-
Pfizer Is Best Positioned Big Pharma in China - Goldman
-
A Possible New Indication for Progenix's Relistor Could Revive Its Fortunes
-
Santarus' Zegrid Facing Back-to-Back FDA Approval Dates
-
Competition in Blood - Thinners: Win - Win for Everyone Involved
-
Thursday, November 19th
Big Pharma Under Pressure as Drug Patents Expire and Pipeline Slows
-
NeurogesX: Next Stop, U.S. Market